← Oncology Approval Tracker

FDA DECISION ·

Tagrisso

osimertinib · AstraZeneca

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant therapy after tumor resection for non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation identified by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

Brought EGFR-targeted treatment to the postoperative setting for patients with specified mutations.

What research teams should watch

Use surgical tissue for timely testing and coordinate the postoperative adjuvant treatment sequence.

PRIMARY RECORDS

Sources